IN8BIO INC
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
INAB$0.93+11.6%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(In thousands, except share and per share data)
| September 30, | ||
|---|---|---|
| 2024 | December 31, | |
| (unaudited) | 2023 | |
| Assets · (Note 2) | ||
| Current assets | ||
| Cash | $4,001 | $21,282 |
| Prepaid expenses and other current assets | 2,702 | 3,343 |
| Total Current Assets | 6,703 | 24,625 |
| Non-current assets | ||
| Property and equipment, net | 3,081 | 3,514 |
| Construction in progress | — | 182 |
| Deferred issuance costs | 181 | — |
| Restricted cash | 259 | 256 |
| Right-of-use assets - finance leases | 1,302 | 1,364 |
| Right-of-use assets - operating leases | 4,116 | 3,513 |
| Other non-current assets | 324 | 255 |
| Total Non-Current Assets | 9,263 | 9,084 |
| Total Assets | $15,966 | $33,709 |
| Liabilities and Stockholders' Equity | ||
| Liabilities | ||
| Current liabilities | ||
| Accounts payable | $1,137 | $924 |
| Accrued expenses and other current liabilities | 769 | 2,955 |
| Short-term finance lease liability | 809 | 694 |
| Short-term operating lease liability | 920 | 820 |
| Total Current Liabilities | 3,635 | 5,393 |
| Long-term finance lease liability | 399 | 525 |
| Long-term operating lease liability | 3,344 | 2,854 |
| Total Non-Current Liabilities | 3,743 | 3,379 |
| Total Liabilities | 7,378 | 8,772 |
| Stockholders' Equity | ||
| Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized at September 30, 2024 and December 31, 2023, respectively. No shares issued and outstanding | — | — |
| Common stock, par value $0.0001 per share; 490,000,000 shares authorized at September 30, 2024 and December 31, 2023; 46,786,948 and 43,287,325 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 5 | 4 |
| Additional paid-in capital | 124,079 | 116,152 |
| Accumulated deficit | (115,496) | (91,219) |
| Total Stockholders' Equity | 8,588 | 24,937 |
| Total Liabilities and Stockholders' Equity | $15,966 | $33,709 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.